Penumbra’s first quarter saw robust demand across its U.S. thrombectomy business, a trend management attributed to continued physician adoption of proprietary CABT (computer-assisted blood clot thrombectomy) technology and the successful launch of new devices. CEO Adam Elsesser highlighted that clinical evidence supporting CABT’s benefits, especially in venous thromboembolism (VTE), drove significant conversion from traditional treatments. The strong product mix and operational efficiencies contributed to margin expansion, while international results were tempered by ongoing weakness in China. As Elsesser noted, “Our strong first quarter results underscore Flash 2.0’s durable growth and momentum in VTE, with 2.0’s demonstrated value proposition continuing to drive conversions.”

Is now the time to buy PEN? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Penumbra’s Q1 Earnings Call

• Robbie Marcus (JPMorgan) asked for color on stroke versus peripheral thrombectomy trends; CEO Adam Elsesser explained that U.S. stroke business grew above market rates, aided by new product launches and strong physician adoption.
• Lynn (Wells Fargo, for Larry Biegelsen) inquired about the FDA review timeline for Thunderbolt; Elsesser refrained from predicting timing but emphasized confidence in the clinical data submitted and relevance of new procedural metrics.
• Pito Chickering (Deutsche Bank) pressed on international thrombectomy growth outside China; Elsesser confirmed ongoing traction in markets with reimbursement, but reiterated that U.S. growth will remain dominant in the near term.
• Bill Plovanic (Canaccord) asked about volume versus pricing in arterial products; Elsesser clarified that recent growth was volume-driven, with minimal price impact, as new cases are being converted from open surgery.
• Travis Steed (Bank of America) sought insight on Ruby XL’s market opportunity; Elsesser noted early physician interest and described the product as built on Penumbra’s core coil platform, with market potential to become clearer after initial adoption.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace of adoption for new product launches such as Ruby XL and the outcome of the Thunderbolt FDA review, (2) continued U.S. thrombectomy market share gains and conversion from traditional therapies, and (3) progress in operational efficiency and early signs of international expansion offsetting China headwinds. Sustained margin improvement and execution of the clinical evidence strategy will also be key markers for Penumbra’s performance.

Penumbra currently trades at $257.01, down from $278.39 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.